Revenue
2020
2021
2022
2023
2024
2025
Fulcrum Therapeutics, Inc. (FULC)
Price$3.85Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $80.0M | $2.8M | $6.3M | $19.2M | $8.8M | — | — |
| Research & development | $56.1M | $63.4M | $71.8M | $76.8M | $69.7M | $59.0M | $71.1M | $25.2M |
| Operating expenses | $84.8M | $101.9M | $113.5M | $118.9M | $100.2M | $80.4M | $84.2M | $33.5M |
| Operating income | −$84.8M | −$21.9M | −$110.7M | −$112.6M | −$81.1M | −$71.6M | −$84.2M | −$33.5M |
| Operating margin | — | −27.37% | −3,945.24% | −1,774.85% | −422.97% | −811.64% | — | — |
| EBITDA | −$83.4M | −$20.3M | −$108.5M | −$110.1M | −$78.5M | −$69.2M | −$82.2M | −$32.2M |
| EBITDA margin | — | −25.38% | −3,867.81% | −1,736.79% | −409.85% | −784.68% | — | — |
| Net income | −$74.9M | −$9.7M | −$97.3M | −$109.9M | −$80.8M | −$70.8M | −$82.7M | −$32.6M |
| Net profit margin | — | −12.16% | −3,470.05% | −1,732.43% | −421.89% | −802.66% | — | — |
| Basic EPSper basic share | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 | -$2.79 | -$8.13 | -$31.14 |
| Diluted EPSper diluted share | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 | -$2.79 | -$8.13 | -$31.14 |
Owners
Reported shareholders
14.35%of listed shares
Nantahala Capital Management, LLC10.95M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Nantahala Capital Management, LLC | 14.35%10.95M shares |
BlackRock, Inc. | 11.57%8.82M shares |
EcoR1 Capital, LLC | 8.59%6.55M shares |
TANG CAPITAL MANAGEMENT LLC | 8.55%6.52M shares |
RA Capital Healthcare Fund LP / Kolchinsky Peter / Shah Rajeev M. / RA CAPITAL MANAGEMENT, L.P. | ≈7.94%6.05M shares |
MONTANOVA CAPITAL, LLC | 4.83%3.68M shares |
D. E. Shaw & Co., Inc. | 3.99%3.04M shares |
CITADEL ADVISORS LLC | 3.55%2.7M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.54%2.7M shares |
JANE STREET GROUP, LLC | 2.91%2.22M shares |
STATE STREET CORP | 2.67%2.04M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.62%2M shares |
GSK plc | 2.34%1.79M shares |
Qube Research & Technologies Ltd | 2.29%1.75M shares |
Assenagon Asset Management S.A. | 2.19%1.67M shares |
RENAISSANCE TECHNOLOGIES LLC | 2.16%1.65M shares |
ADAR1 Capital Management, LLC | 2.05%1.57M shares |
MILLENNIUM MANAGEMENT LLC | 1.95%1.49M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.88%1.43M shares |
MARSHALL WACE, LLP | 1.78%1.36M shares |
Percentages use 76.29M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | Ezekowitz AlanDirector | SellCommon Stock | 18.0K | $3.65 | $65.7K | 10.9K |
| Feb 2, 2026Form 4 | Gould Robert JDirector | SellCommon Stock | 15.0K | $10.72 | $160.8K | 454.9K |
| Jan 2, 2026Form 4/A | Gould Robert JDirector | SellCommon Stock | 15.0K | $10.87 | $163.1K | 469.9K |
| Jan 2, 2026Form 4 | Gould Robert JDirector | SellCommon Stock | 15.0K | $11.87 | $178.1K | 469.9K |
| Dec 15, 2025Form 4 | Oltmans Curtis GaleChief Legal Officer | SellCommon Stock | 3.5K | $12.92 | $44.6K | 10.3K |